Table 1.

Additional efficacy data for Lassa fever vaccines in Guinea pig and NHP models of infection.

Vaccine	Antigen, strain	Animal model	Dose	Dose no.	Measurement of:		Day of challenge	Challenge strain(s)	Survival	Ref.
					T cells	Antibodies
Vaccinia-Lister viral vector	NP, GA391	Hartley Guinea pigs	1 × 107 PFU	1	---	---	28	GA391	100%	[67]
Vaccinia-NYBH viral vector	GPC or NP, Josiah	Strain 13 Guinea pigs	1 × 107 PFU	1	---	X	28	Josiah	94% NP, 79% GPC	[75]
	GPC, Josiah	Rhesus macaques	1 × 109 PFU	1	---	X	28 to 37	Josiah	100%	[76]
	GPC or GPC + NP, Josiah	Rhesus and cynomolgus macaques	1 × 109 PFU	1 or 2	---	X	62 to 488	Josiah	88% GPC, 90% GPC + NP	[77]
Inactivated LASV	Whole virus, unknown	Rhesus macaques	---	6	---	X	108	---	0%	[50]
Venezuelan equine encephalitis virus replicon	GPC or NP, Josiah	Strain 13 Guinea pigs	1 × 107 IU	3	---	X	84	Josiah	100% GPC, 100% NP	[82]
Yellow fever 17D viral vector	GPC, AV	Strain 13 Guinea pigs	1 × 105 PFU	1	---	X	21	Josiah	80%	[79]
	GP1+GP2, Josiah	Strain 13 Guinea pigs	5 × 106 PFU	2	---	X	44	Josiah	83%	[80]